Loading...
CSL logo

CSL LimitedASX:CSL Aktienübersicht

Marktkapitalisierung AU$85.9b
Aktienkurs
AU$178.11
n/v
1Y-34.9%
7D-2.3%
Wert des Portfolios
​
Siehe

CSL Limited

ASX:CSL Lagerbericht

Marktkapitalisierung: AU$85.9b

CSL (CSL) Aktienübersicht

CSL Limited ist in der Forschung, Entwicklung, Herstellung, Vermarktung und dem Vertrieb von biopharmazeutischen Produkten und Impfstoffen in Australien, den Vereinigten Staaten, Deutschland, Großbritannien, der Schweiz, China, Hongkong und international tätig. Mehr Details

CSL grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung6/6
Künftiges Wachstum1/6
Vergangene Leistung4/6
Finanzielle Gesundheit5/6
Dividenden4/6

Belohnungen

39.4% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 10.11% pro Jahr

Die Erträge sind in den letzten 5 Jahren um 3.9% pro Jahr gestiegen.

Im Vergleich zu Wettbewerbern und der Branche gut bewertet

Analysten sind sich einig, dass der Aktienkurs um 28.7%

Risikoanalyse

Bei unseren Risikoprüfungen wurden keine Risiken für CSL festgestellt.

CSL Community Fair Values

Create Narrative

See what 312 others think this stock is worth. Follow their fair value or set your own to get alerts.

CSL logo
CSL

CSL: Share Price Correction Will Present Opportunity As Vaccine Uncertainty Eases

Key Takeaways Operational transformation and investment in innovation are expected to drive margin expansion, earnings growth, and faster introduction of high-value therapies. Market expansion, a focused business structure, and strong demand for plasma and specialty products support sustainable top-line growth and premium positioning.
View narrative
AU$232.54
FV
23.4% unterbewertet intrinsischer Abschlag
4.07%
Revenue growth p.a.
2.1k
users have viewed this narrative
2users have liked this narrative
0users have commented on this narrative
152users have followed this narrative
CSL logo
CSL

CSL will thrive with an 18% profit surge ahead

this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam
View narrative
AU$239.81
FV
25.7% unterbewertet intrinsischer Abschlag
6.48%
Revenue growth p.a.
46
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
CSL logo
CSL

Margin Recovery And Operating Model Simplification Will Support A Stronger Long Term Outlook

Catalysts About CSL CSL is a global biopharmaceutical group focused on plasma derived therapies, vaccines and specialty medicines for rare and serious diseases. What are the underlying business or industry changes driving this perspective?
View narrative
AU$289.37
FV
38.4% unterbewertet intrinsischer Abschlag
5.76%
Revenue growth p.a.
357
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
View Stock Community
UNCY logo
Unicycive Therapeutics

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

View narrative
880
users have viewed this narrative
4users have liked this narrative
0users have commented on this narrative
14users have followed this narrative
US$21.53
67.9% unterbewertet intrinsischer Abschlag
stuart_roberts's Fair Value
Profit Margin
20%
Future PE
27x
Price in 2030
US$34.67

CSL Limited Wettbewerber

Preisentwicklung & Leistung

Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für CSL
Historische Aktienkurse
Aktueller AktienkursAU$178.11
52-Wochen-HochAU$277.18
52-Wochen-TiefAU$168.00
Beta0.28
1 Monat Veränderung3.58%
3 Monate Veränderung1.00%
1 Jahr Veränderung-34.89%
3 Jahre Veränderung-42.19%
5 Jahre Veränderung-34.89%
Veränderung seit IPO22,163.97%

Aktuelle Nachrichten und Updates

Recent updates

CSL Limited's (ASX:CSL) Share Price Not Quite Adding Up

Sep 25
CSL Limited's (ASX:CSL) Share Price Not Quite Adding Up

Is CSL Limited (ASX:CSL) Trading At A 43% Discount?

Aug 07
Is CSL Limited (ASX:CSL) Trading At A 43% Discount?

Here's Why CSL (ASX:CSL) Can Manage Its Debt Responsibly

Jun 14
Here's Why CSL (ASX:CSL) Can Manage Its Debt Responsibly

Weekly Picks: 🧠 Alphabet’s AI edge, CSL’s pricing power, and a chip underdog

Apr 16
Weekly Picks: 🧠 Alphabet’s AI edge, CSL’s pricing power, and a chip underdog

CSL is undervalued in High Tax Scenario

CSL Behring: This is CSL's largest segment and the global leader (#1) in plasma therapies within an estimated US$30 billion industry.11 It focuses on researching, developing, manufacturing, and distri
User avatar

Advancements In iNOMi Technology And HEMGENIX Will Strengthen Market Position

Advancements in plasma collection and operational efficiencies are set to reduce costs and improve CSL Behring's margins, potentially boosting overall earnings.

Aktionärsrenditen

CSLAU BiotechsAU Markt
7D-2.3%-2.1%-1.5%
1Y-34.9%-36.0%4.8%

Rendite im Vergleich zur Industrie: CSL übertraf die Branche Australian Biotechs , die im vergangenen Jahr eine Rendite von -36 erzielte.

Rendite vs. Markt: CSL hinter dem Markt Australian zurück, der im vergangenen Jahr eine Rendite von 4.8 erzielte.

Preisvolatilität

Is CSL's price volatile compared to industry and market?
CSL volatility
CSL Average Weekly Movement2.7%
Biotechs Industry Average Movement11.1%
Market Average Movement9.3%
10% most volatile stocks in AU Market17.5%
10% least volatile stocks in AU Market3.3%

Stabiler Aktienkurs: CSL hatte in den letzten 3 Monaten im Vergleich zum Australian -Markt keine signifikante Preisvolatilität.

Volatilität im Zeitverlauf: CSLDie wöchentliche Volatilität (3%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

GegründetMitarbeiterCEOWebsite
191629,904Paul McKenziewww.csl.com

CSL Limited beschäftigt sich mit der Forschung, Entwicklung, Herstellung, Vermarktung und dem Vertrieb von biopharmazeutischen Produkten und Impfstoffen in Australien, den Vereinigten Staaten, Deutschland, Großbritannien, der Schweiz, China, Hongkong und international. Das Unternehmen ist in den Segmenten CSL Behring, CSL Seqirus und CSL Vifor tätig. Das Segment CSL Behring produziert, vermarktet und vertreibt Plasmaprodukte, Gentherapien und Rekombinanten.

CSL Limited's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von CSL im Vergleich zum Marktanteil des Unternehmens?
CSL grundlegende Statistiken
MarktanteilAU$85.87b
Gewinn(TTM)AU$4.29b
Umsatz(TTM)AU$22.22b
20.0x
Kurs-Gewinn-Verhältnis
3.9x
Kurs-Umsatz-Verhältnis

Ist CSL zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
CSL Gewinn- und Verlustrechnung (TTM)
EinnahmenUS$15.56b
Kosten der EinnahmenUS$7.48b
BruttogewinnUS$8.08b
Sonstige AusgabenUS$5.08b
GewinnUS$3.00b

Zuletzt gemeldete Gewinne

Jun 30, 2025

Datum des nächsten Gewinnberichts

Feb 10, 2026

Gewinn per Aktie (EPS)6.23
Bruttomarge51.93%
Nettogewinnspanne19.30%
Schulden/Eigenkapital-Verhältnis45.9%

Wie hat sich CSL auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

2.3%
Aktuelle Dividendenrendite
47%
Ausschüttungsquote

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/02/03 17:33
Aktienkurs zum Tagesende2026/02/03 00:00
Gewinne2025/06/30
Jährliche Einnahmen2025/06/30

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite. Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

CSL Limited wird von 25 Analysten beobachtet. 16 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Saul HadassinBarrenjoey Markets Pty Limited
Thomas WakimBell Potter
Lyanne HarrisonBofA Global Research